{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:23:06Z","timestamp":1778750586504,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013117","name":"International Fibrodysplasia Ossificans Progressiva Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013117","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.bone.2021.116016","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T12:52:44Z","timestamp":1621428764000},"page":"116016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva"],"prefix":"10.1016","volume":"150","author":[{"given":"Frederick S.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Andolina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edna E.","family":"Mancilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward C.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Al Mukaddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Rocke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Pignolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2021.116016_bb0005","unstructured":"Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. In Emerging Concepts in Pediatric Bone Disease. Pediatric Endocrinology Reviews. 10(S-2): 437\u2013448, 2013."},{"key":"10.1016\/j.bone.2021.116016_bb0010","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/jbmr.2728","article-title":"The natural history of flare-ups in fibrodysplasia ossificans progressiva: a comprehensive global assessment","volume":"31","author":"Pignolo","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116016_bb0015","doi-asserted-by":"crossref","unstructured":"Pignolo R.J., Baujat G, Brown MA, DeCunto C, DiRocco M, Hsiao EC, Keen R, Al Mukaddam M, LeQuan Sang K-H, Wilson A, White B, Grogan DR, Kaplan FS. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J. Rare Dis. 2019; 14: 98. doi:https:\/\/doi.org\/10.1186\/s13023-019-1068-7.","DOI":"10.1186\/s13023-019-1096-3"},{"key":"10.1016\/j.bone.2021.116016_bb0020","doi-asserted-by":"crossref","unstructured":"Pignolo RJ, Cheung K. Kile S, Fitzpatrick MA, DeCunto C, Al Mukaddam M, Hsiao EC, Baujat G, Delai P, Eekhoff, EMW, DiRocco M, Grunwald Z, Haga N, Keen R, Levi B, Morhart R, Scott C, Sherman A, Zhang K, Kaplan FS. Self-reported baseline phenotypes from the International Fibrodysplasia Ossificans Progressiva (FOP) Association global registry. Bone. 2020 May;134:115274.","DOI":"10.1016\/j.bone.2020.115274"},{"key":"10.1016\/j.bone.2021.116016_bb0025","unstructured":"Kaplan FS, Al Mukaddam M, Baujat G, Brown M, Cali A, Cho T-J, Crowe C, DeCunto C, Delai P, Diecidue, R, Di Rocco M, Eekhoff EMW, Friedman C, Grunwald Z, Haga N. Hsiao E, Keen R, Kitterman J, Levy C, Morhart R, Netelenbos C, Scott C, Shore EM, Zasloff M, Zhang K, Pignolo RJ. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc. Intl. Clin. Council FOP: 1:1\u2013111, 2019."},{"issue":"6","key":"10.1016\/j.bone.2021.116016_bb0030","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/bcp.13823","article-title":"Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva","volume":"85","author":"Wentworth","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2021.116016_bb0035","doi-asserted-by":"crossref","unstructured":"Pignolo RJ & Kaplan FS. Druggable targets, clinical trial design and proposed pharmacological management in fibrodysplasia ossificans progressiva. Expert Opin. Orphan Drugs doi:https:\/\/doi.org\/10.1080\/21678707.2020.1751122.","DOI":"10.1080\/21678707.2020.1751122"},{"key":"10.1016\/j.bone.2021.116016_bb0040","doi-asserted-by":"crossref","unstructured":"Hsaio EC, DiRocco M, Cali A. Zasloff M, Al Mukaddam M, Pignolo R, Grunwald Z, Netelenbos C, Keen R, Baujat G, Brown MA, Cho T-J De Cunto C, Delai P, Haga N, Morhart R, Scott C, Zhang K, Diecidue RJ, Friedman CS, Kaplan FS, Eekhoff EMW. Special considerations for clinical trials in fibrodysplasia ossificans progressiva. Br. J. Clin. Pharmacol. 85 (6): 1119\u20131207, 2019.","DOI":"10.1111\/bcp.13777"},{"key":"10.1016\/j.bone.2021.116016_bb0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bone.2021.116016_bb0050","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bone.2021.116016_bb0055","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1053\/hupa.2001.26464","article-title":"Mast cell involvement in fibrodysplasia ossificans progressiva","volume":"32","author":"Gannon","year":"2001","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bone.2021.116016_bb0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bone.2021.116016_bb0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.116016_bb0070","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/ard.2004.029835","article-title":"Inhibition of c-kit tyrosine kinase by Imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis","volume":"64","author":"Juurikivi","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.bone.2021.116016_bb0075","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/art.23698","article-title":"Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate","volume":"58","author":"Pannu","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2021.116016_bb0080","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bone.2021.116016_bb0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00774-011-0323-3","article-title":"Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro","volume":"30","author":"J\u00f6nsson","year":"2012","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2021.116016_bb0090","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/09546634.2013.802274","article-title":"Role of Imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report","volume":"6","author":"Agarwala","year":"2013","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.bone.2021.116016_bb0095","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1872213X113079990021","article-title":"Imatinib mesylate: an innovation in treatment of autoimmune diseases","volume":"3","author":"Azizi","year":"2013","journal-title":"Recent Patents Inflamm. Allergy Drug Discov."},{"key":"10.1016\/j.bone.2021.116016_bb0100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.nmd.2012.10.025","article-title":"Imatinib attenuates severe mouse dystrophy and inhibits proliferation and fibrosis-marker expression in muscle mesenchymal progenitors","volume":"23","author":"Ito","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bone.2021.116016_bb0105","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11420-013-9335-y","article-title":"Use of Imatinib in prevention of heterotopic ossification","volume":"9","author":"Werner","year":"2013","journal-title":"HSSJ"},{"key":"10.1016\/j.bone.2021.116016_bb0110","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/jbmr.2848","article-title":"Cellular hypoxia promotes heterotopic ossification by amplifying BMP signaling","volume":"31","author":"Wang","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116016_bb0115","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1056\/NEJMoa1613125","article-title":"KIT inhibition by imatinib in patients with severe refractory asthma","volume":"376","author":"Cahill","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.116016_bb0120","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.116016_bb0125","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jbmr.3304","article-title":"Depletion of Mast cells and macrophages impairs heterotopic ossification in an ACVR1 (R206H) mouse model of fibrodysplasia ossificans progressiva","volume":"33","author":"Convente","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116016_bb0130","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bone.2017.07.019","article-title":"Early clinical observations on the use of imatinib mesylate in FOP: a report of seven cases","volume":"109","author":"Kaplan","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.116016_bb0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0022-3956(02)00057-2","article-title":"Unique design issues in clinical trials of patients with bipolar affective disorder","volume":"37","author":"Post","year":"2003","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.bone.2021.116016_bb0140","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ng1783","article-title":"A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva","volume":"38","author":"Shore","year":"2006","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.bone.2021.116016_bb0145","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/humu.20868","article-title":"Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1","volume":"30","author":"Kaplan","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bone.2021.116016_bb0150","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cytogfr.2009.10.006","article-title":"The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling","volume":"20","author":"Kaplan","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"issue":"4","key":"10.1016\/j.bone.2021.116016_bb0155","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nm.2334","article-title":"Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-\u03b3 agonists","volume":"17","author":"Shimono","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2021.116016_bb0160","doi-asserted-by":"crossref","unstructured":"Hatsell SJ, Idone V, Wolken DM, Huang L, Kim HJ, Wang L, Wen X, Nannuru KC, Jimenez J, Xie L, Das N, Makhoul G, Chernomorsky R, D'Ambrosio D, Corpina RA, Schoenherr CJ, Feeley K, Yu PB, Yancopoulos GD, Murphy AJ, Economides AN. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci. Transl. Med. 2015;Sep 2;7(303):303ra137.","DOI":"10.1126\/scitranslmed.aac4358"},{"key":"10.1016\/j.bone.2021.116016_bb0165","doi-asserted-by":"crossref","unstructured":"Hino K, Ikeya M, Horigome K, Matsumoto Y, Ebise H, Nishio M, Sekiguchi K, Shibata M, Nagata S, Matsuda S, Toguchida J. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. PNAS 2015; doi:https:\/\/doi.org\/10.1073\/pnas.1510540112.","DOI":"10.1073\/pnas.1510540112"},{"key":"10.1016\/j.bone.2021.116016_bb0170","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.semcdb.2015.12.013","article-title":"Granting immunity to FOP and catching heterotopic ossification in the act","volume":"49","author":"Kaplan","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bone.2021.116016_bb0175","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41467-018-02872-2","article-title":"Activin-dependent signaling in fibro\/adipogenic progenitors causes fibrodysplasia ossificans progressiva","volume":"9","author":"Lees-Shepard","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bone.2021.116016_bb0180","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221001782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221001782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:42:49Z","timestamp":1762659769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221001782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":36,"alternative-id":["S8756328221001782"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.116016","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.116016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116016"}}